These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 7900854)
1. Apolipoprotein AI levels are increased in part as a consequence of reduced catabolism in nephrotic rats. Kaysen GA; Hoye E; Jones H Am J Physiol; 1995 Mar; 268(3 Pt 2):F532-40. PubMed ID: 7900854 [TBL] [Abstract][Full Text] [Related]
2. Effect of oncotic pressure on apolipoprotein A-I metabolism in the rat. Kaysen GA; Hoye E; Jones H; van Tol A; Joles JA Am J Kidney Dis; 1995 Jul; 26(1):178-86. PubMed ID: 7611250 [TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein gene expression in analbuminemic rats and in rats with Heymann nephritis. Sun X; Jones H; Joles JA; van Tol A; Kaysen GA Am J Physiol; 1992 May; 262(5 Pt 2):F755-61. PubMed ID: 1590420 [TBL] [Abstract][Full Text] [Related]
4. Effect of plasma oncotic pressure on apolipoprotein levels in rats with Heymann nephritis. Kaysen GA; Jones H; Joles JA; van Tol A Miner Electrolyte Metab; 1996; 22(1-3):31-8. PubMed ID: 8676821 [TBL] [Abstract][Full Text] [Related]
5. High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria. Saku K; Mendoza SG; Laver M; Hynd BA; Gartside PS; Kashyap ML Nephron; 1988; 50(2):112-5. PubMed ID: 3146703 [TBL] [Abstract][Full Text] [Related]
6. Endothelial chylomicron binding is altered by interaction with high-density lipoprotein in Heymann's nephritis. Shearer GC; Couser WG; Kaysen GA Am J Kidney Dis; 2001 Dec; 38(6):1385-9. PubMed ID: 11728980 [TBL] [Abstract][Full Text] [Related]
7. Role of lipoprotein lipase in the regulation of high density lipoprotein apolipoprotein metabolism. Studies in normal and lipoprotein lipase-inhibited monkeys. Goldberg IJ; Blaner WS; Vanni TM; Moukides M; Ramakrishnan R J Clin Invest; 1990 Aug; 86(2):463-73. PubMed ID: 2117022 [TBL] [Abstract][Full Text] [Related]
8. Chronic hypothyroidism induces abnormal structure of high-density lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Huesca-Gómez C; Franco M; Luc G; Montaño LF; Massó F; Posadas-Romero C; Pérez-Méndez O Metabolism; 2002 Apr; 51(4):443-50. PubMed ID: 11912551 [TBL] [Abstract][Full Text] [Related]
9. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409 [TBL] [Abstract][Full Text] [Related]
10. Plasma IgG pool is not defended from urinary loss in nephrotic syndrome. al-Bander HA; Martin VI; Kaysen GA Am J Physiol; 1992 Mar; 262(3 Pt 2):F333-7. PubMed ID: 1558152 [TBL] [Abstract][Full Text] [Related]
11. Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy. Toledo-Ibelles P; Franco M; Carreón-Torres E; Luc G; Tailleux A; Vargas-Alarcón G; Fragoso JM; Aguilar-Salinas C; Luna-Luna M; Pérez-Méndez O Metabolism; 2013 Apr; 62(4):492-8. PubMed ID: 23089050 [TBL] [Abstract][Full Text] [Related]
12. Tissue sites of degradation of apoprotein A-I in the rat. Glass CK; Pittman RC; Keller GA; Steinberg D J Biol Chem; 1983 Jun; 258(11):7161-7. PubMed ID: 6406495 [TBL] [Abstract][Full Text] [Related]
13. Graded effects of proteinuria on HDL structure in nephrotic rats. Shearer GC; Newman JW; Hammock BD; Kaysen GA J Am Soc Nephrol; 2005 May; 16(5):1309-19. PubMed ID: 15788471 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of gemfibrozil on lipoprotein metabolism. Saku K; Gartside PS; Hynd BA; Kashyap ML J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042 [TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375 [TBL] [Abstract][Full Text] [Related]
16. Catabolism of very low density lipoproteins in experimental nephrosis. Garber DW; Gottlieb BA; Marsh JB; Sparks CE J Clin Invest; 1984 Oct; 74(4):1375-83. PubMed ID: 6480830 [TBL] [Abstract][Full Text] [Related]
17. High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study. Frénais R; Ouguerram K; Maugeais C; Mahot P; Maugère P; Krempf M; Magot T Diabetologia; 1997 May; 40(5):578-83. PubMed ID: 9165227 [TBL] [Abstract][Full Text] [Related]
18. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Shearer GC; Stevenson FT; Atkinson DN; Jones H; Staprans I; Kaysen GA Kidney Int; 2001 Jan; 59(1):179-89. PubMed ID: 11135070 [TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates. Carreón-Torres E; Rendón-Sauer K; Monter-Garrido M; Toledo-Ibelles P; Gamboa R; Menjivar M; López-Marure R; Luc G; Fievet C; Cruz D; Vargas-Alarcón G; Pérez-Méndez O Clin Chim Acta; 2009 Mar; 401(1-2):37-41. PubMed ID: 19036342 [TBL] [Abstract][Full Text] [Related]
20. Pioglitazone increases the fractional catabolic and production rates of high-density lipoproteins apo AI in the New Zealand White Rabbit. Carreón-Torres E; Juárez-Meavepeña M; Cardoso-Saldaña G; Gómez CH; Franco M; Fievet C; Luc G; Juárez-Oropeza MA; Pérez-Méndez O Atherosclerosis; 2005 Aug; 181(2):233-40. PubMed ID: 16039276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]